Mary Wiggin

A Retrospective Real-World Analysis Demonstrating the Value of Azstarys for Patients With Attention-Deficit Hyperactivity Disorder

Abstract: Aim: To quantify the value of Azstarys (serdexmethylphenidate/dexmethylphenidate) for patients with attention-deficit hyperactivity disorder (ADHD) with real-world data from the...

Meg Corliss ;

Mary Wiggin ;

01/19/2023

Evaluation of Skin Adhesion and Local Skin Tolerability of Once-Weekly Donepezil Transdermal System: Results of a Phase 1 Trial in Healthy Volunteers

Abstract: Donepezil transdermal system (TDS; Adlarity®) is approved for dementia of the Alzheimer’s type. Reported here are skin-adhesion and skin-tolerability evaluations of donepezil TD...

Charles Oh ;

Mary Wiggin ;

01/19/2023

Bioequivalence and Safety Comparison of Once-Weekly Donepezil Transdermal System With Oral Donepezil: Results of a Phase 1 Pharmacokinetic Study in Healthy Volunteers

Abstract: Oral donepezil is widely prescribed for dementia of the Alzheimer’s type. Donepezil transdermal system (TDS; Adlarity®) was also recently approved. Here, we report bioequivalenc...

Charles Oh ;

Mary Wiggin ;

01/19/2023

Serdexmethylphenidate/Dexmethylphenidate Effects on Sleep in Children With Attention-Deficit Hyperactivity Disorder

Abstract: Aim: To determine sleep behavior during serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH) treatment in children with attention-deficit hyperactivity disorder (ADHD). Method...

Mary Wiggin ;

Greg Mattingly , MD;

01/19/2023

Serdexmethylphenidate/Dexmethylphenidate for Children With Attention-Deficit Hyperactivity Disorder: Reduction in Disorder Severity From a Laboratory Classroom Study

Abstract: Aim: To evaluate changes in attention-deficit hyperactivity disorder (ADHD) severity in children (aged 6-12 years) posttreatment with serdexmethylphenidate/dexmethylphenidate (S...

Matthew Brams ;

Mary Wiggin ;

01/19/2023